Abstract:Pancreatic cancer, often termed the "silent killer" due to its vague symptoms and late diagnosis, continues to challenge oncologists with its significant treatment challenges and poor prognosis. Standard-of-care regimens, such as FOLFIRINOX (FFX) and Gemcitabine + nab-paclitaxel (GnP), show varied efficacy among patients. Understanding the factors that contribute to these varied responses is crucial for advancing personalized treatment strategies. This study uses NetraAI, a novel machine learning (ML) approach to analyze whole genome sequencing (WGS) and RNA sequencing (RNASeq) data from pancreatic ductal adenocarcinoma (PDAC) subjects (n=208) prior to FFX or GnP first-line combination therapy from the COMPASS trial, aiming to identify key variables that distinguish between responses to these two therapeutic regimens. NetraAI identifies explainable subpopulations within clinical trial data defined by a set of driving variables (i.e., hypotheses) related to drug response. This approach focuses on explaining only subjects that collectively represent a real effect and does not forcibly explain everyone, to avoid overfitting. Our analysis identified several key factors significantly correlating with treatment response. Downregulated LRRC8E and upregulated PTPRH showed favourable response to GnP, while upregulated UTG1A13p was associated with FFX response. Across all patients (stable disease, partial response, complete response) CLEC19A and LRRC29 expression were associated with better response to both FFX and GnP, suggesting that they may play a role in the chemotherapy response mechanisms. The NetraGPT module, leverages large language models (LLMs) and NetraAI insights to further query trial results. Querying NetraGPT, we identified a link between LRRC29 and HOOK1, associated with SHP, which has been linked to GnP response in non-small cell lung cancer. These findings suggest that chemotherapy response may be cancer-agnostic, depending on the chemotherapeutic agent, with LRRC29 expression discriminating selecting GnP versus FFX treatment. Our findings highlight the potential of AI in elucidating complex relationships within clinical trial data, offering valuable insights into the determinants of treatment response in pancreatic cancer to achieve more personalized cancer care. The identified biomarkers provide a promising foundation for developing personalized treatment strategies, enhancing the precision of therapeutic decisions. Integrating explainable ML methods for small and medium sized clinical data with LLMs provides an exciting step forward. Retrieval Augmentation allows researchers to create LLMs that are designed to answer questions about heterogeneous patient populations through the vantage of the various insights that have been discovered via specialized ML methods such as NetraAI and its NetraGPT module. We will provide a demo of how an interactive LLM was used to derive new insights into PDAC that may pave the way to precision treatment and explain how researchers can begin to create their own versions of these tools. Citation Format: Joseph Geraci, Bessi Qorri, Mike Tsay, Christian Cumbaa, Paul Leonchyk, Larry Alphs, Luca Pani. An AI approach to unraveling treatment response in pancreatic cancer: Insights from the COMPASS trial leveraging large language models (LLMs) [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research; 2024 Sep 15-18; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl_2) nr B066.

Abstract 2315: AI-enabled precision oncology era: Advanced and interactive interpretation of next-gneneration sequencing (NGS) reports

Precision Oncology and AI: the ACMA System for Personalized Treatment Matching Using Real-World Data.

Abstract 6214: OncodynamiX as an artificial intelligence (AI) based platform for precision medicine

Leveraging State-of-the-Art AI Algorithms in Personalized Oncology: From Transcriptomics to Treatment

Abstract 5721: Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival

Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives

Abstract 4971: Integrating artificial intelligence and functional precision oncology for individualized cancer therapies

Abstract 755: Supporting Precision Cancer Treatment Decision with Functional Evaluation of Cancer Gene Mutations and Variants

Abstract B066: An AI approach to unraveling treatment response in pancreatic cancer: Insights from the COMPASS trial leveraging large language models (LLMs)

Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy.

Abstract 3509: Using generative AI for filtering and comprehension of drug target discovery screen results

Abstract LB396: The power of NetraAI: Precision medicine in oncology through sub-insight learning from small data sets

Artificial intelligence assists precision medicine in cancer treatment

Abstract 3548: OKAIN: A comprehensive oncology knowledgebase for the interpretation of clinically actionable alterations

Abstract 3982: Prediction and Selection of Cancer Drug Treatments Using Personalized Tumor Models or Models with Matching Genomic Profiles

Abstract 4298: Predicting tumor evolution from digital histology using AI

Abstract 7402: Foundation AI models predict molecular measurements of tumor purity

Leveraging Large Language Models for Decision Support in Personalized Oncology

Abstract PO4-01-10: Multi-modal artificial intelligence models from baseline histopathology predict prognosis in HR+ HER2- early breast cancer

From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

Abstract 4090: Creating research quality cancer genomic data from electronic health records